Product Launch
Ibrutinib’s Breakthrough to Market
FDA’s new Breakthrough Therapies designation sped Pharmacyclics/J&J’s ibrutinib (brand name: Imbruvica) through regulatory review in four months, based on Phase 2 studies. Pricing and access issues, though, may not get resolved so quickly ...Read more
Big Data
Seeing Beyond the Big Data Backlash
There has been a lot of talk lately that ‘Big Data’ is just BS. Peter Houston looks beyond the hype to reveal what companies should be focusing on. Data quality matters more than quantity, and proper analytics matter more than almost anything else. Most importantly, data however large bears no relevance so long as you don’t use it and use it well ...Read more
Market Access
Payers: Late for the Party?
PharmExec’s latest roundtable featured a panel of experts that examined the current environment for market access to the latest medicines. With innovative therapies facing increased scrutiny and increased pricing pressures, it’s easy to see that payers are skeptical given potential cost exposures. Bill Looney suggests that pharma’s C-suite could make for a better negotiator if it paid more attention to its more or less isolated market access teams ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
New Markets, New Media
Pharma Needs To Do More Than Attract Digital Talent
As the digital component to marketing becomes more and more essential to pharma’s brand management, many people within and around the industry have wondered, “Can pharma attract the right talent for the job?” Peter Houston points to a gap beginning to widen in digital know-how between the drug industry and other sectors, which could be mitigated by putting the proper support and training in place for digital teams ...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
|
